- Home
- ATOS vs DBI Comparison
ATOS vs DBI Comparison
Compare ATOS & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- DBI
- Stock Information
- Founded
- ATOS 2009
- DBI 1991
- Country
- ATOS United States
- DBI United States
- Employees
- ATOS N/A
- DBI N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- ATOS Health Care
- DBI Consumer Discretionary
- Exchange
- ATOS Nasdaq
- DBI Nasdaq
- Market Cap
- ATOS 120.4M
- DBI 138.7M
- IPO Year
- ATOS 2012
- DBI 1991
- Fundamental
- Price
- ATOS $0.86
- DBI $3.73
- Analyst Decision
- ATOS Strong Buy
- DBI Hold
- Analyst Count
- ATOS 3
- DBI 2
- Target Price
- ATOS $6.25
- DBI $4.50
- AVG Volume (30 Days)
- ATOS 1.3M
- DBI 621.3K
- Earning Date
- ATOS 11-12-2025
- DBI 12-09-2025
- Dividend Yield
- ATOS N/A
- DBI 5.37%
- EPS Growth
- ATOS N/A
- DBI N/A
- EPS
- ATOS N/A
- DBI N/A
- Revenue
- ATOS N/A
- DBI $2,917,437,000.00
- Revenue This Year
- ATOS N/A
- DBI N/A
- Revenue Next Year
- ATOS N/A
- DBI $2.53
- P/E Ratio
- ATOS N/A
- DBI N/A
- Revenue Growth
- ATOS N/A
- DBI N/A
- 52 Week Low
- ATOS $0.55
- DBI $2.18
- 52 Week High
- ATOS $1.66
- DBI $6.29
- Technical
- Relative Strength Index (RSI)
- ATOS 39.96
- DBI 53.73
- Support Level
- ATOS $0.86
- DBI $3.51
- Resistance Level
- ATOS $0.91
- DBI $3.99
- Average True Range (ATR)
- ATOS 0.05
- DBI 0.17
- MACD
- ATOS -0.02
- DBI 0.03
- Stochastic Oscillator
- ATOS 4.01
- DBI 58.91
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.